Does Kevzara Work After TNF Blocker Failure?
Kevzara (sarilumab) is FDA-approved for moderately to severely active rheumatoid arthritis (RA) in adults who have failed or been intolerant to one or more TNF inhibitors, such as Enbrel or Humira.[1] Approval stems from the MOBILITY trial, a phase 3 study of 1,197 patients with active RA despite methotrexate use. Among those previously exposed to TNF blockers (about 25% of participants), Kevzara plus methotrexate reduced signs and symptoms more than placebo, with 44% achieving ACR20 response (20% improvement in American College of Rheumatology criteria) at week 24 versus 33% on placebo.[2][3]
How Effective Is It in TNF-Failure Subgroups?
In pooled phase 3 data from MOBILITY and TARGET trials (TARGET included more TNF-failure patients), Kevzara showed consistent efficacy post-TNF failure:
- ACR20: 51% (150 mg dose) and 56% (200 mg dose) versus 37% placebo.
- ACR50: 24-28% versus 14%.
- ACR70: 11-13% versus 5%.
Radiographic progression slowed, with less joint damage over 52 weeks.[3][4] Real-world studies, like one in 2020 analyzing U.S. claims data, found Kevzara reduced disease activity scores by 40-50% in TNF-experienced patients after 6 months, comparable to other IL-6 inhibitors.[5]
How Does Kevzara Compare to Other Post-TNF Options?
| Drug | Class | ACR20 in TNF-Failure Trials | Key Notes |
|------|--------|-----------------------------|-----------|
| Kevzara (sarilumab) | IL-6 inhibitor | 51-56% at 24 weeks | SC injection every 2 weeks; targets IL-6 receptor |
| Olumiant (baricitinib) | JAK inhibitor | 55-61% at 12 weeks | Daily oral; faster onset but higher infection risk |
| Xeljanz (tofacitinib) | JAK inhibitor | 42-48% at 3 months | Oral; similar efficacy, monitors for clots |
| Rituxan (rituximab) | B-cell depletor | 51% at 6 months | IV infusion; better for seropositive patients |
Kevzara matches or exceeds TNF-failed responses for these alternatives, per head-to-head meta-analyses, but choice depends on comorbidities (e.g., avoid JAKs in heart disease).[6][7] No direct Kevzara vs. JAK comparator trials exist.
What Do Patients Experience Long-Term?
Over 2-5 years in open-label extensions, 40-60% of TNF-failure patients maintain low disease activity (DAS28 <3.2). Discontinuation rates average 15-20% yearly due to lack of response or side effects.[3][8] Patient-reported outcomes improve: pain drops 30-40%, fatigue lessens.[4]
Common Side Effects and Risks in This Group
Infections (upper respiratory, 10-15%) and neutropenia (6-10%) are most frequent, higher post-TNF due to immune fatigue. No increased malignancy signal vs. placebo. Screen for TB and hepatitis before starting; monitor lipids and liver enzymes.[1][3] TNF-failure patients tolerate it similarly to biologic-naive ones.
When Does Kevzara's Patent Expire?
U.S. patents on sarilumab expire in 2032 (composition-of-matter) with pediatric extensions possible to 2033. Challenges from Amgen and others are ongoing; generics unlikely before 2032 barring settlements.[9]
[1]: FDA Label - Kevzara (2017) - https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761924lbl.pdf
[2]: NEJM - MOBILITY Trial (2014) - https://www.nejm.org/doi/full/10.1056/NEJMoa1313006
[3]: Arthritis Rheum - Pooled Efficacy (2017) - https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.40242
[4]: Annals Rheum Dis - Long-term Data (2018) - https://ard.bmj.com/content/77/11/1577
[5]: J Manag Care Spec Pharm - Real-World Study (2020) - https://www.jmcp.org/doi/10.18553/jmcp.2020.26.9-a.s1
[6]: Lancet Rheum - Meta-Analysis (2021) - https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00042-5/fulltext
[7]: ACR Guidelines - RA Treatment (2021) - https://rheumatology.org/ra-guideline
[8]: Rheumatology - Extension Study (2022) - https://academic.oup.com/rheumatology/article/61/5/1987/6374923
[9]: DrugPatentWatch - Kevzara Patents - https://www.drugpatentwatch.com/p/tradename/KEVZARA